An updated analysis of the epidemiologic trends of neuroendocrine tumors in Taiwan

doi:10.1038/s41598-021-86839-2

. 2021 Apr 12;11(1):7881.

doi: 10.1038/s41598-021-86839-2.

An updated analysis of the epidemiologic trends of neuroendocrine tumors in Taiwan

Jeffrey S Chang¹, Li-Tzong Chen^{1

2

3}, Yan-Shen Shan^{4

5}, Pei-Yi Chu^{1

6

7}, Chia-Rong Tsai¹, Hui-Jen Tsai^{8

9

10}

Affiliations

¹ National Institute of Cancer Research, National Health Research Institutes, 1F No 367, Sheng-Li Road, Tainan, 70456, Taiwan.
² Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
³ Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
⁴ Department of Surgery, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
⁵ Institute of Clinical Medicine, National Cheng Kung University, Tainan, Taiwan.
⁶ Department of Pathology, Show Chwan Memorial Hospital, Changhua, Taiwan.
⁷ School of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan.
⁸ National Institute of Cancer Research, National Health Research Institutes, 1F No 367, Sheng-Li Road, Tainan, 70456, Taiwan. hjtsai@nhri.org.tw.
⁹ Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan. hjtsai@nhri.org.tw.
¹⁰ Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan. hjtsai@nhri.org.tw.

PMID: 33846396
PMCID: PMC8041887
DOI: 10.1038/s41598-021-86839-2

An updated analysis of the epidemiologic trends of neuroendocrine tumors in Taiwan

Jeffrey S Chang et al. Sci Rep. 2021.

. 2021 Apr 12;11(1):7881.

doi: 10.1038/s41598-021-86839-2.

Authors

Jeffrey S Chang¹, Li-Tzong Chen^{1

2

3}, Yan-Shen Shan^{4

5}, Pei-Yi Chu^{1

6

7}, Chia-Rong Tsai¹, Hui-Jen Tsai^{8

9

10}

Affiliations

¹ National Institute of Cancer Research, National Health Research Institutes, 1F No 367, Sheng-Li Road, Tainan, 70456, Taiwan.
² Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
³ Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
⁴ Department of Surgery, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
⁵ Institute of Clinical Medicine, National Cheng Kung University, Tainan, Taiwan.
⁶ Department of Pathology, Show Chwan Memorial Hospital, Changhua, Taiwan.
⁷ School of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan.
⁸ National Institute of Cancer Research, National Health Research Institutes, 1F No 367, Sheng-Li Road, Tainan, 70456, Taiwan. hjtsai@nhri.org.tw.
⁹ Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan. hjtsai@nhri.org.tw.
¹⁰ Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan. hjtsai@nhri.org.tw.

PMID: 33846396
PMCID: PMC8041887
DOI: 10.1038/s41598-021-86839-2

Abstract

The incidence of neuroendocrine tumors (NETs) has been increasing in recent decades. Previously, we reported the incidence and survival of NETs in Taiwan by analyzing the 1996-2008 data from the Taiwan Cancer Registry. Here we performed an updated analysis on the incidence and survival of NETs in Taiwan from 1996 to 2015. The incidence of NETs was 0.244 per 100,000 in 1996 and increased to 3.162 per 100,000 in 2015. The most common site of NETs was rectum (29.65%), followed by lung/bronchus (17.22%), and pancreas (10.71%). The 5- and 10-year overall survival rates of all NETs were 54.6% and 45.3%, respectively. Female and younger NETs patients had a better survival. The survival of all NETs diagnosed between 2010 and 2015 was better than those diagnosed between 2004 and 2009. Among the common sites of NETs, an improved survival of pancreatic NETs diagnosed between 2010 and 2015 compared to those diagnosed between 2004 and 2009 was observed. Overall, the incidence of NETs in Taiwan has continued to increase. The survival of pancreatic NET has shown a recent improvement. The development of novel therapeutic agents has the potential to improve the prognosis of NETs of other sites in the near future.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

**Figure 1**
The annual incidence of NETs in Taiwan from 1996 to 2015. (A) The annual incidence of NETs of all sites in men, women and both. (B) The annual incidence of NETs in the 10 most common sites of NETs. Age-standardized incidence rates were calculated by direct standardization to the age distribution of the 2000 WHO standard population.

**Figure 2**
The overall survival of NETs. (A) The overall survival of NETs for all patients (B) The overall survival of NETs by sex. (C) The overall survival of NETs in the 6 most common sites.

See this image and copyright information in PMC

Cited by

Sex Differences in Survival from Neuroendocrine Neoplasia in England 2012-2018: A Retrospective, Population-Based Study.
White BE, Russell B, Remmers S, Rous B, Chandrakumaran K, Wong KF, Van Hemelrijck M, Srirajaskanthan R, Ramage JK. White BE, et al. Cancers (Basel). 2023 Mar 20;15(6):1863. doi: 10.3390/cancers15061863. Cancers (Basel). 2023. PMID: 36980749 Free PMC article.
Emerging Precision Medicine Approaches for Lung Neuroendocrine Tumors.
Mulvey CK. Mulvey CK. Cancers (Basel). 2023 Nov 25;15(23):5575. doi: 10.3390/cancers15235575. Cancers (Basel). 2023. PMID: 38067279 Free PMC article. Review.
Update on Epidemiology, Diagnosis, and Biomarkers in Gastroenteropancreatic Neuroendocrine Neoplasms.
Takayanagi D, Cho H, Machida E, Kawamura A, Takashima A, Wada S, Tsunoda T, Kohno T, Shiraishi K. Takayanagi D, et al. Cancers (Basel). 2022 Feb 22;14(5):1119. doi: 10.3390/cancers14051119. Cancers (Basel). 2022. PMID: 35267427 Free PMC article. Review.
[Clinical significance of neuroendocrine tumors : Incidence, symptoms, diagnosis, stage, and prognostic factors and their influence on disease management].
Hartrampf PE, Serfling SE, Higuchi T, Bojunga J, Weich A, Werner RA. Hartrampf PE, et al. Radiologie (Heidelb). 2024 Jul;64(7):536-545. doi: 10.1007/s00117-024-01315-y. Epub 2024 May 22. Radiologie (Heidelb). 2024. PMID: 38777918 Review. German.
Clinical Evaluation of Response to Octreotide and Chemotherapy in High-Grade Malignant Neuroendocrine Tumors and Promising In Vitro Preclinical Results with Pasireotide.
Doello K, Chico MA, Quiñonero F, Ortiz R, Prados J, Mesas C, Melguizo C. Doello K, et al. Medicina (Kaunas). 2024 Jun 25;60(7):1039. doi: 10.3390/medicina60071039. Medicina (Kaunas). 2024. PMID: 39064468 Free PMC article.

See all "Cited by" articles

References

1. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, et al. One hundred years after "carcinoid": Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J. Clin. Oncol. 2008;26:3063–3072. doi: 10.1200/JCO.2007.15.4377. - DOI - PubMed
1. Hauso O, Gustafsson BI, Kidd M, Waldum HL, Drozdov I, Chan AK, Modlin IM. Neuroendocrine tumor epidemiology: Contrasting Norway and North America. Cancer. 2008;113:2655–2664. doi: 10.1002/cncr.23883. - DOI - PubMed
1. Tsai HJ, Wu CC, Tsai CR, Lin SF, Chen LT, Chang JS. The epidemiology of neuroendocrine tumors in Taiwan: A nation-wide cancer registry-based study. PLoS ONE. 2013;8:e62487. doi: 10.1371/journal.pone.0062487. - DOI - PMC - PubMed
1. Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, Shih T, Yao JC. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3:1335–1342. doi: 10.1001/jamaoncol.2017.0589. - DOI - PMC - PubMed
1. Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Bläker M, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID Study Group. J. Clin. Oncol. 2009;27:4656–4663. doi: 10.1200/JCO.2009.22.8510. - DOI - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations

[1] Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, et al. One hundred years after "carcinoid": Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J. Clin. Oncol. 2008;26:3063–3072. doi: 10.1200/JCO.2007.15.4377. - DOI - PubMed

[2] Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, et al. One hundred years after "carcinoid": Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J. Clin. Oncol. 2008;26:3063–3072. doi: 10.1200/JCO.2007.15.4377. - DOI - PubMed

[3] Hauso O, Gustafsson BI, Kidd M, Waldum HL, Drozdov I, Chan AK, Modlin IM. Neuroendocrine tumor epidemiology: Contrasting Norway and North America. Cancer. 2008;113:2655–2664. doi: 10.1002/cncr.23883. - DOI - PubMed

[4] Hauso O, Gustafsson BI, Kidd M, Waldum HL, Drozdov I, Chan AK, Modlin IM. Neuroendocrine tumor epidemiology: Contrasting Norway and North America. Cancer. 2008;113:2655–2664. doi: 10.1002/cncr.23883. - DOI - PubMed

[5] Tsai HJ, Wu CC, Tsai CR, Lin SF, Chen LT, Chang JS. The epidemiology of neuroendocrine tumors in Taiwan: A nation-wide cancer registry-based study. PLoS ONE. 2013;8:e62487. doi: 10.1371/journal.pone.0062487. - DOI - PMC - PubMed

[6] Tsai HJ, Wu CC, Tsai CR, Lin SF, Chen LT, Chang JS. The epidemiology of neuroendocrine tumors in Taiwan: A nation-wide cancer registry-based study. PLoS ONE. 2013;8:e62487. doi: 10.1371/journal.pone.0062487. - DOI - PMC - PubMed

[7] Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, Shih T, Yao JC. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3:1335–1342. doi: 10.1001/jamaoncol.2017.0589. - DOI - PMC - PubMed

[8] Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, Shih T, Yao JC. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3:1335–1342. doi: 10.1001/jamaoncol.2017.0589. - DOI - PMC - PubMed

[9] Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Bläker M, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID Study Group. J. Clin. Oncol. 2009;27:4656–4663. doi: 10.1200/JCO.2009.22.8510. - DOI - PubMed

[10] Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Bläker M, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID Study Group. J. Clin. Oncol. 2009;27:4656–4663. doi: 10.1200/JCO.2009.22.8510. - DOI - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

An updated analysis of the epidemiologic trends of neuroendocrine tumors in Taiwan

Affiliations

An updated analysis of the epidemiologic trends of neuroendocrine tumors in Taiwan

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Other Literature Sources

Abstract

Conflict of interest statement

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

Related information

LinkOut - more resources

Full Text Sources

Other Literature Sources